Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT00474448 |
Other study ID # |
H07-00457 |
Secondary ID |
|
Status |
Completed |
Phase |
|
First received |
|
Last updated |
|
Start date |
May 2007 |
Est. completion date |
February 2014 |
Study information
Verified date |
May 2017 |
Source |
University of British Columbia |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
The purpose of this study is to assess the health-related quality of life of subjects who
have Hereditary Multiple Exostoses and to develop a disease specific quality of life survey.
The investigators hypothesize that there are a wide range of quality of life experiences for
patients with this syndrome.
Description:
At the time of recruitment, subjects will be asked to indicate whether they would like to
participate in a one-time survey, or are willing to participate in the initial survey plus
two additional questionnaire administrations, thereafter, which will be used to develop the
disease-specific quality of life (QOL) score. All participants will complete either the SF-36
survey (for adult HME subjects) or the CHQ PF (for parents of children with HME), as
applicable, in addition to a blank form with categorical subheadings (such as recreation,
social function, etc.), which they will use to address any issues not covered in the
standardized questionnaire. Standardized questionnaires will be scored and analyzed. The
items listed on the second form will be compiled and reapplied to subjects that indicated
interest in extended participation in survey completion. Subjects will be asked to determine
which items apply to them and to rank these applicable items in order of importance. The
results from this will be used to develop a 30 question, disease-specific questionnaire. The
final step will be to readminister this survey, in conjunction with the SF-36 or CHQ PF, and
follow up, in two weeks, with a second administration of the aforementioned surveys, in order
to test the variability and validity of the disease-specific, health-related, quality of life
score.